The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
The company is eyeing a launch for its IVD kits at the beginning of next year, as evidence grows for the integration of TMB analysis into the clinical care of cancer patients.
Investigators and commercial firms presenting at the recent AACR meeting highlighted how heterogeneous both the technology and the application of liquid biopsy remains.
The company presented three posters at AACR, two of which demonstrated insights from its circulating DNA monitoring in colorectal and bladder cancers.
The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.
In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
Investigators from several centers outlined tumor features, treatment strategies, and clinical trial classifications coming from tumor-germline clinical sequencing programs.
Conducting studies on Latina and African-American women produces population-specific insights on the genetics of the disease that aren't possible to glean in European-heavy GWAS.
Plenary session Chairwoman Elaine Mardis said the presentations made it clear how great the need is for interdisciplinary science as data becomes ever more complex.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.